Victoza overview
Brand name for liraglutide 1.8 mg daily, FDA-approved for type 2 diabetes mellitus.
Victoza at a glance
Manufacturer
Novo Nordisk
FDA status
FDA-approved
Questions readers ask
What is Victoza approved for, and at what dose?
Victoza is Novo Nordisk’s brand of liraglutide 1.8 mg taken daily, FDA-approved for type 2 diabetes mellitus. This page does not list a chronic weight management indication for it.
How does Victoza’s ingredient compare with weekly GLP-1 drugs on weight-loss data?
This page gives no Victoza weight-loss figures. Benchmarks: semaglutide 2.4 mg averaged −14.9% at 68 weeks in STEP 1, and tirzepatide 15 mg averaged −20.9% at 72 weeks in SURMOUNT-1 (treatment-regimen estimand).
Does the Medicare GLP-1 Bridge cover Victoza?
Victoza is not on the Bridge list. The Bridge (July 1, 2026 to Dec 31, 2027) gives eligible Part D members a $50 copay for Wegovy, Foundayo and Zepbound KwikPen, with prior authorization and BMI-based criteria.
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Registered outsourcing facilities (503B)
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
- Wegovy (semaglutide) prescribing information, Novo Nordisk